Key result
Catheter-based renal denervation is highlighted as a potential therapeutic option to improve glycaemic control in patients with resistant hypertension based on pilot studies and case reports.
Why the study?
Does catheter-based renal denervation improve glycaemic control in patients with resistant hypertension and diabetes?
Does catheter-based renal denervation improve glycaemic control in patients with resistant hypertension and diabetes?
This review highlights the potential of renal denervation as a novel therapeutic option to improve glycaemic control in patients with resistant hypertension and metabolic disease.
Answers are grounded in this paper and cite their sources.
Renal denervation should not yet change practice for glycaemic control; leaves open the need for randomized trials in resistant hypertension with diabetes.
Catheter-based renal denervation (RDN) has been shown to reduce sympathetic nerve activity and blood pressure in patients with resistant hypertension. Increased central sympathetic activity is a main contributor to the pathophysiology of several important chronic cardiovascular diseases, including diabetes and the metabolic syndrome. Indeed several recently published pilot studies and case reports suggest beneficial effects of RDN on glucose metabolism in patients with resistant hypertension. This review highlights the background of approaching the renal sympathetic nerves as a potential new therapeutic option to improve glycaemic control in patients with resistant hypertension.
No takes yet. Share an insight, caveat, or question.
Mahfoud et al. (2013) conducted a review in Resistant hypertension and diabetes. Catheter-based renal denervation was evaluated on Glycaemic control. Catheter-based renal denervation is highlighted as a potential therapeutic option to improve glycaemic control in patients with resistant hypertension based on pilot studies and case reports.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: